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Tissue Specificity of Human Disease 
Module
Maksim Kitsak1,2, Amitabh Sharma1,2,3, Jörg Menche1,2,4,5, Emre Guney1,2,6, 
Susan Dina Ghiassian1,2,7, Joseph Loscalzo8 & Albert-László Barabási1,2,4,7,8,9
Genes carrying mutations associated with genetic diseases are present in all human cells; yet, clinical 
manifestations of genetic diseases are usually highly tissue-specific. Although some disease genes are 
expressed only in selected tissues, the expression patterns of disease genes alone cannot explain the 
observed tissue specificity of human diseases. Here we hypothesize that for a disease to manifest itself 
in a particular tissue, a whole functional subnetwork of genes (disease module) needs to be expressed 
in that tissue. Driven by this hypothesis, we conducted a systematic study of the expression patterns 
of disease genes within the human interactome. We find that genes expressed in a specific tissue 
tend to be localized in the same neighborhood of the interactome. By contrast, genes expressed in 
different tissues are segregated in distinct network neighborhoods. Most important, we show that it 
is the integrity and the completeness of the expression of the disease module that determines disease 
manifestation in selected tissues. This approach allows us to construct a disease-tissue network that 
confirms known and predicts unexpected disease-tissue associations.
The rapidly increasing knowledge of the role of genetic variants in human disease raises an important question: 
Why do pathologic variants that exist in the genome of every organ or tissue affect primarily specific tissues, like 
asthma affecting the lung or schizophrenia the brain? After all, the mutated genes are present in all cells. The 
accepted answer holds that genes associated with asthma may be expressed only in the lung and those associated 
with schizophrenia may show elevated expression only in the brain, eliminating the impact of disease-causing 
variants in other tissues. This assumption is, however, typically not valid: many disease-associated genes are 
expressed in multiple tissues, most of which do not show pathophysiological manifestations of the disease or of 
any functional abnormality1,2. Consider, for example, Huntington’s disease, a neurodegenerative genetic disorder 
caused by a mutation of the HTT gene (excessive repeats of the trinucleotide CAG). As shown in Fig. 1A, we find 
that HTT is significantly expressed in CD34 T cells ( = .⁎z 1 83E ), CD56 NK cells ( = .
⁎z 2 63E ), and X721 B lympho-
blasts ( = .⁎z 5 99E ), prompting us to ask again, why do the mutations of HTT not cause pathophysiological changes 
in these non-neural tissues?
The driving hypothesis of this paper is that the expression of genes carrying the disease-associated mutation 
in a particular tissue or organ does not fully explain the tissue-specificity of the disease. Instead, it is the integrity 
of the cellular subnetwork induced by all disease-associated genes that determines the manifestation of a disease 
in the tissue. Throughout the text we refer to this cellular subnetwork as a disease module3–8.
Thus, to understand disease manifestations or pathophenotypes, it is not sufficient to focus narrowly on dis-
ease genes and their expression patterns; we must also determine the presence/absence of the disease module, i.e., 
the tissue-dependent subnetwork, whose breakdown may be responsible for the disease.
This hypothesis is supported by several recent findings. First, disease-associated genes are more likely to 
exhibit tissue-specific expression than non-disease-associated genes2,9–11. The integration of gene expression, 
disease manifestation, molecular network connectivity, and tissue specificity data leads to better predictions of 
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novel disease-gene candidates than any of these elements alone9. Similarly, a tissue-specific interactome consid-
erably improves disease gene prioritization compared to prioritization derived from a generic interactome12. Our 
hypothesis is further supported by recent evidence that disease-causing genes tend to have elevated transcript 
level and increased number of tissues-specific protein interactions in their disease tissue2. Similarly, tissue-specific 
networks were found to accurately predict lineage-specific responses to perturbations, allowing the development 
of software packages that return the tissue-specific interaction landscape of selected genes1.
To test the interplay between the disease module and tissues, we analyze the expression patterns of disease 
genes and genes in their network vicinity in the human interactome3,4,13,14. We show that (i) genes expressed 
in a specific tissue are localized in the same neighborhood of the interactome, being in each other’s close 
network-based proximity; (ii) genes expressed in different tissues are segregated in distinct network neighbor-
hoods; and (iii) the integrity of the expression of the disease module determines disease manifestations in selected 
tissues. These findings offer an accurate and self-consistent formalization of tissue-specificity of human disease 
modules15, offering the graph-theoretical underpinning of relating diseases to specific tissues, consistent with the 
numerous empirical and experimental studies1,2,9–12.
Results
Tissue-Specific Expression Patterns in the Interactome. In our analysis we use experimentally docu-
mented molecular interactions as compiled by Menche et al.15. The resulting interactome contains 141, 296 phys-
ical interactions between 13, 460 proteins, including protein-protein and regulatory interactions, and metabolic 
pathway and kinase-substrate interactions. To identify the tissue-dependent patterns of expression of each gene, 
we use global gene expression data for 64 non-diseased tissues from the GNF Atlas16. To combine the interactome 
with the gene expression data we consider molecular interactions only among 10, 434 proteins that were anno-
tated to probe ids (see Supplementary Section II).
Further, we consider a protein-coding gene to be expressed in a tissue if its expression level in this tissue is 
significantly higher than in other tissues. We use z-scores to quantify expression significance and define the 
Figure 1. Network-based localization of expressed genes. (A) The distribution of expression levels of the 
HTT gene across 64 non-diseased tissues. (B) The distribution of the mean shortest distance dS for randomly 
chosen sets of genes in the human interactome. The number of randomly selected genes in each set is chosen 
to match the number of genes expressed in prefrontal cortex at zE ≥ 1.0. Note that the observed mean shortest 
distance for genes expressed in prefrontal cortex, dprefr.cort = 1.22, is significantly lower than the random 
expectation. (C) The distribution of the connected components size, P(S), for randomly chosen sets of genes 
in the human interactome. The number of randomly selected genes in each set is chosen to match the number 
of genes expressed in prefrontal cortex at zE ≥ 1.0. Note that the size of the connected component for genes 
expressed in prefrontal cortex, Sprefr.cort = 2, 001, is significantly greater than the random expectation.
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significance level at = .⁎z 1 0E  (see Methods and Fig. S1). At this threshold, on average only 10% of genes are 
expressed in a tissue, ranging from 0.6% for ovary to 44% for X721 B lymphoblasts ( Fig. 2A). We also repeated 
our calculations for a more stringent threshold of = .⁎z 2 0E , with similar outcomes. We next identified all diseases 
defined by MeSH that have at least 20 associated genes in the current OMIM and GWAS database17,18, and then 
filtered out overly-inclusive diseases, yielding a list of 70 diseases (see Supplementary Section II).
To illustrate the impact of tissue-specific gene expression patterns on the interactome, consider prefrontal 
cortex tissue, in which only 2, 644 of the 10, 434 expressed genes are expressed with significance zE ≥ 1.0. We first 
asked: are the expressed genes distributed randomly in the interactome or do they tend to agglomerate in some 
well-defined network neighborhood? We relied on two network-based measures to address this question. (i) We 
measured the network-based mean shortest distance15 among 2, 644 expressed genes, finding 〈 dprefr.cort〉 = 1.22, 
significantly smaller than the random expectation, 〈 〉 = ..d 1 33prefr cort
random  (p value = 8.9 × 10−17, z score = − 11.0) 
(Fig. 1B). (ii) We next found that 75% of the expressed genes form a single connected subgraph (connected com-
ponent in graph theory19) (Sprefr.cort = 2, 001, Fig. 1C). This value is significantly greater than the random expecta-
tion, =.S 1, 715prefr cort
random  (p value = 8.7 × 10−10, z score = 6.02) (Fig. 1C) (see Supplementary Section III).
Taken together, these results show that the genes expressed in the prefrontal cortex are localized in the same 
neighborhood of the interactome, and that a very significant fraction of them forms a single connected subgraph. 
This pattern is not unique to the prefrontal cortex. Indeed, we find that a significant fraction of expressed genes 
forms a single connected subgraph in 41 of the 64 tissues considered here (see Figs 2, S2 and S3), indicating that 
each tissue has a characteristic interactome neighborhood in which its proteins agglomerate.
Given that on average only 10% of all genes are expressed in any specific tissue, we next asked: are the genes 
expressed in different tissues localized in the same or different network neighborhoods? Consider, for example, 
the hypothalamus and the lung, with nhypothalamus = 1, 354 and nlung = 1, 141 genes expressed at zE ≥ 1.0. The num-
ber of genes simultaneously expressed in these tissues is nhl = 84, significantly lower than the random expectation, 
=n 148hl
rand  (Jaccard index (see Supplementary Section II), Jhl = 0.035, = .J 0 063hl
random , p value = 4.5 × 10−9). We 
also find that the network-based mean shortest distance between gene pairs expressed in the two tissues, 
dAB = 1.30, is significantly larger than random expectation = .d 1 26AB
random  (p value = 0.034, z score = 1.82) (see 
Supplementary Section IV). Taken together, these results indicate that the genes expressed in the hypothalamus 
and the lung are distinct, and that their proteins are located in different interactome neighborhoods.
In contrast, genes expressed in the hypothalamus and prefrontal cortex exhibit both significant overlap and 
network-based colocalization: nhypothalamus = 1, 354 and nprefr.cortex = 2, 644, with overlap of n = 992, significantly 
greater than the random expectation, nrand = 343 (Jhl = 0.33, = .J 0 12hl
random , p value = 2.4 × 10−14). In addition, the 
Figure 2. Localization statistics for 41 tissues where a significant fraction of expressed genes forms a 
connected subgraph. (A) The total number of expressed genes (black), the number of genes constituting the 
largest connected component (module size, red), and the mean shortest distance, dS (module diameter, blue), 
calculated for 41 tissues where a significant fraction of expressed genes form a connected subgraph. (B) The 
significance of the observed largest connected components (red) and the significance of the mean shortest 
distance (blue). The horizontal dashed line corresponds to z = 1.6.
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mean shortest distance between gene pairs expressed in the two tissues is dAB = 0.69, significantly smaller than 
= .d 1 13AB
random  (p value < 10−152, z score = − 26.4) (see Supplementary Section II and Fig. S4).
We systematically measured the network-based mean shortest distances dAB between gene sets expressed at 
zE ≥ 1.0 for all 2, 016 possible tissue pairs. For 1, 415 pairs, the network-based separation is significantly different 
from the random expectation. Of these, 851 tissue pairs are closer than expected by chance, while 564 pairs show 
a statistically significant separation. The obtained 1, 415 separations allowed us to build a dendrogram for the 
hierarchy of tissue clusters (see Fig. S5), predicting three major clusters, one of which consists of several subclus-
ters and contains brain regions, and the remaining contain immune system cells and reproductive tissues.
Taken together, we find that genes expressed in a particular tissue are not scattered randomly throughout the 
interactome, but tend to form a well-localized connected subnetwork. Subnetworks corresponding to similar 
tissues tend to overlap, but pathologically distinct tissue pairs tend to agglomerate in different neighborhoods of 
the interactome. Hence, we can divide the interactome into tissue-specific neighborhoods, a partition that has direct 
implications for our understanding of diseases, as we next demonstrate.
Disease-Tissue Associations. To illustrate how a disease manifests itself in a particular tissue, consider 
tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of τ protein within 
neurons. We find that several genes associated with tauopathies, such as the MAPT gene (involved in production 
of τ proteins), are expressed in many tissues, indicating that gene expression alone is a poor predictor of the 
tissue-specificity of the disease. According to our hypothesis, tauopathies manifest mainly in the brain because 
the subnetwork of proteins supporting the relevant molecular mechanisms for the disease are expressed integrally 
only in brain tissue.
In support of this hypothesis, we find that the expressed tauopathies genes connect to each other to form 
a statistically significant connected component only in six tissues, all of which belong to the nervous system 
(Fig. 3A–F): amygdala, hypothalamus, prefrontal cortex, spinal cord, thalamus, and whole brain. For compari-
son we also show the subnetwork of tauopathies-related genes in endothelial cells and lymph nodes, where the 
expressed disease genes do not form a significant connected component, a pattern characteristic of the remaining 
60 tissues ( Fig. 3H,I).
Figure 3. Tissue specificity of tauopathies. (A–F,H,I) Expression levels of genes related to tauopathies in  
(A) amygdala, (B) hypothalamus, (C) prefrontal cortex, (D) spinal cord, (E) thalamus, (F) whole brain, 
(H) CD105-positive endothelial cells, and (I) lymph node. Node sizes are chosen to reflect the expression 
significance of the corresponding genes. Blue nodes correspond to genes with expression significance zE ≥ 1.0, 
while red nodes correspond to genes with zE < 1.0. (G), A putative disease modules for tauopathies. The 
numbers show the number of specific nervous system tissues in which the corresponding gene is expressed.
www.nature.com/scientificreports/
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Combining these observations, we arrive at a putative disease module for tauopathies consisting of nine genes 
that form a connected subgraph ( Fig. 3G). Three of these, MAPT, APP, and CLU, are simultaneously expressed 
in three of the six brain regions (amygdala, prefrontal cortex, hypothalamus). A key role is played by the amyloid 
precursor protein APP, which not only is the central hub of the module, but also is expressed in all six brain tis-
sues. This network-based conclusion is supported by previous experimental evidence. Indeed, the APP on chro-
mosome 21q21.2 is the first causative gene identified for early onset Alzheimer’s disease20, a disorder that belongs 
to the class of tauopathies. Furthermore, APP and MAPT are known to form soluble complexes that may promote 
the self aggregation of APP into the insoluble forms observed in Alzheimer’s disease21. In the nervous system, the 
expression of CLU (clusterin) is elevated in neuropathological conditions, such as Alzheimer’s disease, where CLU 
co-precipitates with APP, suggesting a physiological interaction22. Finally, recent large genome-wide association 
studies have identified loci not previously associated with the disease at the CLU (also known as APOJ) gene 
(rs11136000, p value = 1.4 × 10−9)23. Since TOMM40 is located on chromosome 19, closely adjacent to APOE, 
another gene known to be associated with Alzheimer’s disease24, other investigations have suggested that the 
statistically significant correlation of TOMM40 with Alzheimer’s is due to linkage disequilibrium. By contrast, we 
find APOE in Alzheimer’s disease and tauopathies in the connected subgraph and not TOMM40, which indicates 
a greater mechanistic relevance of APOE for the disease than TOMM40.
This example supports our hypothesis that a disease manifests itself only in tissues in which the expressed 
disease genes form a disease module, i.e., a statistically significant connected subgraph. It also expands earlier 
findings of elevated expression and protein interaction in specific tissues1, indicating that one needs to inspect the 
integrity of the full disease module to establish the tissue-specificity of a given disease. Building on this hypoth-
esis, we identified all diseases that form a significant subgraph in a particular tissue, following the procedure 
depicted in Fig. 4A. This strategy allows us to build a disease-tissue bipartite network that links 70 diseases to 64 
tissues via 187 links (see Fig. 4B, Supplementary Section V, and Fig. S6). While some diseases manifest in as many 
as 12 tissues, on average, each of the diseases included in the network manifests in 2.4 tissues. The tissues with the 
largest number of expressed diseases are BDCA4 dendritic cells (18 diseases), X721 B lymphoblast cells (16 dis-
eases), and CD56 NK cells (12 diseases), appearing as the hubs of the disease-tissue network. For 35 diseases, we 
did not find a statistically significant module in any tissue, and of the 64 tissues included in this analysis, 29 tissues 
did not have any disease associated with them. Plausible reasons for these latter two findings are the incomplete-
ness of the interactome25–28 and the limited number of known disease genes.
In addition to a large number of expected disease-tissue associations (e.g., tauopathies and brain tissues), we 
also find a number of less obvious disease-tissue associations, such as macular degeneration and liver, or lipid 
metabolism disorders and CD14 monocytes. Next, we discuss several examples to illustrate the predictive power 
of the developed map and to validate some of the predicted associations.
Liver. Eight diseases have a statistically significant module in liver tissue. Some, like blood coagulation dis-
orders or certain types of anemia, are expected. Indeed, of the 40 genes related to blood coagulation disorders, 
14 are expressed in liver and 12 of the expressed genes form a single connected subgraph (p value < 10−53, 
z score = 15.4) (see Fig. 5A). Five of them, F5, F7, F9, F10, and F11, are parts of the extrinsic and intrinsic blood 
clotting pathways. Others, like macular degeneration, are somewhat more surprising. Interestingly, seven genes 
associated with macular degeneration (CFH, C3, C2, CFHR5, CFB and CFHR4, CFHR1) also form a statistically 
significant module in liver (p value < 10−26, z score = 10.85, see Fig. 5A). Yet, while macular degeneration is an 
ophthalmologic disorder, there are plausible molecular reasons for this association with the network of expressed 
genes in liver. Indeed, genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, 
are known to be associated with age-related macular degeneration (AMD) (see Fig. 5A). The complement system 
in the blood of mammals comprises more than 30 proteins that are primarily synthesized in the liver and that 
circulate in their inactive forms. In addition, CFH, a major circulating protein, is mainly produced in liver29, and 
livers of patients with AMD are more likely to produce an abnormal form of CFH, which is thought to increase 
inflammation in the eye.
Hypothalamus. In the hypothalamus, only three brain-related diseases form significant modules: tauopathies 
(S = 6, p value < 10−37, z score = 12.9), Alzheimer’s disease (S = 4, p value < 10−17, z score = 8.6), and basal ganglia 
diseases (S = 3, p value = 1.8 × 10−7, z score = 5.1) (see Fig. 5B). We also find a significant module for peroxisomal 
disorders (S = 4, p value < 10−65, z score = 17.1), a class of conditions caused by defects in peroxisome func-
tion. Neurological dysfunction is a prominent feature of most peroxisomal disorders30. Peroxisomal disorders are 
divided into two groups, the peroxisome biogenesis disorders (PBDs) and the peroxisome single-enzyme perox-
isome disorders (PSEDs). The connected component of peroxisomal disorders expressed in the hypothalamus 
consists of PEX19, PEX10, PEX6, and PEX7. PEX7 encodes peroxisome targeting signal receptor, while PEX19 
is proposed to be essential for the proper localization and stability of peroxisomal membrane proteins. At the 
same time, PEX6 is required for membrane fusion in an early step of peroxisome biogenesis31. While tauopathies 
and basal ganglia diseases have overlapping modules, peroxisome disorders are separated from them. Moreover, 
a correlation has been found between the level of peroxisome proliferation in hypothalamus and protection 
from APP (amyloid)-associated neurodegeneration, a process that is linked to Alzheimer’s disease32. Current 
protein-protein interaction maps are estimated to cover 10–15% of all potential interactions26. Hence, the iso-
lation of peroxisome disorders from tauopathies and basal ganglia diseases may be a reflection of this limited 
interactome coverage.
Taken together, the obtained disease-tissue bipartite network supports our hypothesis that disease modules 
are tissue-specific. To validate this disease-tissue network we examined diseases associated with liver and hypo-
thalamus. While most of the observed associations, including blood coagulation disorders and anemia in liver, 
Alzheimer disease, Basal ganglia diseases in hypothalamus are well known, we also identified less known disease 
www.nature.com/scientificreports/
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Figure 4. Disease-tissue bipartite network. (A) From left to right: I. Human interactome is compiled and 
disease-related genes are identified. II. Gene expression data are mapped onto the human interactome. The 
expression level is reflected in the node size. III. A tissue-specific interactome is constructed as a subgraph of 
the human interactome consisting of genes expressed with significance zE ≥ 1.0. Disease A has significantly 
connected module within the tissue-specific interactome, while diseases B and C do not. (B) Disease-tissue 
bipartite network. Tissues are placed within the circle while diseases are positioned along the circumference. 
Nodes are colored according to tissue classification. The sizes of tissue nodes are proportional to the total 
number of genes expressed in them. The widths of connecting links correspond to the significance of the 
association. For higher resolution see Fig. S6.
www.nature.com/scientificreports/
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Figure 5. Diseases associated with liver and hypothalamus. (A) Diseases associated with the liver-specific 
interactome. (B) Diseases associated with the hypothalamus-specific interactome. Node sizes depend on 
the expression significance of the corresponding genes. We use pie-chart coloring to reflect disease-gene 
associations. To improve the readability of diagrams, we grouped genes related to the same disease into modules 
and highlighted each module accordingly. We excluded disease genes associated with nutritional and metabolic 
diseases from both panels owing to the large number of associated genes.
www.nature.com/scientificreports/
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tissue associations of macular generation in liver, and peroxisomal disorder in hypothalamus. Our finding also 
provides new routes to analyze tissue-specific disease modules, helping highlight specific disease genes and the 
molecular mechanisms mediating the pathobiological relationships between diseases.
Tissue-specific disease modules. Genes associated with the same disease are known to have similar bio-
logical characteristics33–35. Yet, the precise mechanistic role at the molecular level remains unknown for most 
disease genes. This prompts us to ask: Could tissue specificity help filter out genes that may have only limited 
mechanistic relevance to a disease? To answer this question, we start by inspecting the functional annotations of 
the disease genes according to the three Gene Ontology categories36: biological processes (bp), molecular func-
tion (mf), and cellular component (cc).
Functional similarity of two genes is defined as the similarity between the sets of their GO annotations37. To 
define functional similarity of two genes we use Simpson and Jaccard similarity coefficients (see Methods). We 
report the results for the Simpson coefficient in the main text; results obtained with Jaccard similarity are qualita-
tively similar and are reported in Supplementary Section IID. The functional similarity of a group of genes is then 
given by the average pairwise functional similarity. For example, for the 40 genes associated with blood coagula-
tion disorders (BCD), the average pairwise biological process similarity is bp(BCD) = 0.36, the average molec-
ular function similarity is mf(BCD) = 0.48, and the average cellular component similarity is cc(BCD) = 0.77 
(Supplementary Section IID). Yet, only 14 of the 40 BCD genes are expressed in liver, and these 14 have higher 
functional similarity values in all three categories: bp(BCD, liver) = 0.44, mf(BCD, liver) = 0.63, and cc(BCD, 
liver) = 0.91, suggesting that the disease genes excluded by tissue specificity are those whose functional related-
ness is smaller.
We, therefore, hypothesize that tissue specificity acts as a “cleansing” or filtering procedure, automatically 
eliminating the potentially false positive BCD genes ( Hypothesis A). Alternatively, the observed increase in the 
functional similarity of disease genes could occur solely due to the fact that tissue-specific genes are functionally 
more uniform ( Hypothesis B).
To test the validity of Hypothesis B we measured tissue-specific GO similarities for all disease-tissue pairs and 
calculated their deviations from GO similarities measured for all disease genes, Δ bp(d, t) = bp(d, t) − bp(d). Here 
bp(d, t) is the biological process similarity of genes associated with disease d that are expressed in tissue t, and 
bp(d) is the biological process similarity of all genes of disease d. We also define Δ mf(d, t) and Δ cc(d, t) in a sim-
ilar way, using molecular function and cellular component categories, respectively (see Supplementary Section 
IID). Positive values of Δ bp(d, t) indicate that tissue-specific disease genes are more similar to each other than 
all genes associated with the disease are similar to each other. For instance, Δ bp(BCD, liver) = 0.08, Δ mf(BCD, 
liver) = 0.15, and Δ cc(BCD, liver) = 0.14.
We first calculated the distributions of the deviations Δ bp(d, t), Δ mf(d, t), and Δ cc(d, t) for all possible 
disease-tissue pairs ( Fig. 6A). For all GO categories, we have nearly equal numbers of disease-tissue pairs with 
positive and negative deviations, which results in median values close to zero ( Fig. 6A). This finding indicates 
that the functional similarity of disease genes Δ bp(d, t) may increase or decrease depending on the disease-tissue 
pair (d, t) considered. Note that if hypothesis B were true, deviations would be positive for all disease-tissue 
pairs, including those diseases that have no significant module in the tissue. Hence, the results of Fig. 6A rule out 
Hypothesis B.
To test Hypothesis A, the expectation that disease genes are functionally more uniform only in tissues in which 
they have a significant connected component, we analyzed the distributions of Δ bp(d, t), Δ cc(d, t), and Δ mf(d, t) 
separately for disease-tissue pairs in which disease genes form a significant connected component (set CC) 
and in which they do not (set N − CC). Even though the two distributions look visually similar ( Fig. 6B–D), 
the Mann-Whitney U test performed to compare the distributions indicates that they are statistically different 
(pbpvalue < 10−74). Of all disease-tissue pairs in CC, 70% have Δ bp(d, t) > 0, and 30% have Δ bp(d, t) < 0 (see top 
inset of Fig. 6B). In the case of N − CC, we observe 39% of disease-tissue pairs with Δ bp(d, t) > 0 and 61% with 
Δ bp(d, t) < 0 (bottom inset of Fig. 6B). We, therefore, find that in 70% of tissues the disease genes become 
functionally more uniform in disease-tissue combinations for which the disease has a significant connected 
component. We obtained similar results for the cellular component category: (pccvalue = 1.7 × 10−7), 79% of 
disease-tissue pairs have Δ cc(d, t) > 0, while 21% have Δ cc(d, t) < 0 (top and bottom insets of Fig. 6C). In the 
case of N − CC we observe that 55% of disease-tissue pairs have Δ cc(d, t) > 0, while 45% have Δ cc(d, t) < 0 (top 
and bottom insets of Fig. 6C). These results did not hold for the molecular functions GO categories ( Fig. 6D): 
(pmfvalue = 0.17). To test the robustness of our results we repeated calculations using the Jaccard coefficient as 
the similarity measure. Obtained results are qualitatively similar to those obtained with the Simpson coefficient 
(see Supplementary Section IID).
Taken together, we find that disease genes expressed in a tissue in which a given disease has a significant con-
nected component are functionally more uniform. Consequently, reducing the disease module to a specific tissue 
acts as a natural filtering procedure, automatically eliminating the functionally and potentially mechanistically 
less relevant disease genes.
To demonstrate how tissue-specificity can be used to filter out less relevant disease gene associations we 
consider genes associated with macular degeneration and arthritis. Figure 7A depicts the correlation between 
the significance of GWAS associations and gene expression levels in liver for macular degeneration. Of the 
15 genes expressed at zE < 1.0, 9 are characterized by relatively low GWAS significance (− Log(p) < 6). Of the 
11 genes expressed at zE ≥ 1.0, 7 have GWAS significance of (− Log(p) > 20) and 4 have GWAS significance of 
(7 < − Log(p) < 12) ( Fig. 7B).
To understand better the liver-specific interactions among the expressed genes we construct the GWAS-based 
subnetwork of macular degeneration genes ( Fig. 7B). We find that 7 genes with GWAS significance − Log(p) > 20 
(C2, C3, CFB, CFH, CFHR1, CFHR4 and CFHR5) form a connected component, while the remaining 4 expressed 
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genes (LIPC, RNF5, CETP, HERPUD1) with lower GWAS significance are not connected ( Fig. 7B). Taken 
together, Fig. 7 indicates that the tissue-specific disease module acts as an effective filter, aggregating the diseases 
genes with high GWAS significance and keeping less relevant genes apart from the disease module.
The analysis of arthritis-related genes expressed in BDCA4 cells is performed in Supplementary Section VI. 
The examples of macular degeneration and arthritis demonstrate the possibility of using tissue-specificity of 
disease modules to filter out less relevant disease genes. Yet, at this time, we can not systematically explore 
tissue-specific filtering effects on all diseases owing to the limited knowledge of GWAS disease-gene associations 
and the incompleteness of the human interactome.
Discussion
In this paper we offer a disease module-based approach towards understanding the tissue specificity of human 
diseases. We showed that for a disease to manifest itself in a particular tissue, a statistically significant functional 
subnetwork of genes associated with the disease needs to be expressed in that tissue. This approach lead to the 
construction of the disease-tissue network that offers a predictive map of the statistically significant disease-tissue 
associations. This approach allowed us to examine known disease-tissue relationships and to predict newly defin-
able disease-tissue associations. We also showed that expressed disease genes tend to be more functionally similar 
if the disease manifests itself in that tissue. These observations can be used as an additional test of the relevance 
of individual genes to disease.
Throughout this paper, we used gene expression to define tissue-specific interactomes and diseases modules. 
We considered a gene expressed in a particular tissue when its expression level exceeds the significance threshold 
of = .⁎z 1 0E . To probe the robustness of our key results, we repeated the analysis for different values of 
⁎zE 
(Supplementary Section V, Figs S4 and S7), finding that:
(i) The localization of disease genes in a particular network-based neighborhood of the human interactome is 
significant for a wide range of ⁎zE values. The higher 
⁎zE, the stronger is the localization, as measured by the mean 
shortest distance among expressed genes.
(ii) The separations between the subnetworks of expressed genes corresponding to dissimilar tissues increases 
as ⁎zE increases.
Figure 6. Functional similarity of tissue-specific disease genes. (A–D), Distributions of changes in GO 
similarities: (A), The distributions of Δ bp(d, t), Δ cc(d, t), and Δ mf(d, t) obtained for all disease-tissue pairs. 
Measured mean similarity values are, respectively, M(Δ bp) = 7.6 × 10−3, M(Δ cc) = 0.034, and M(Δ mf) =  
− 6.3 × 10−3. (B), Δ bp(d, t), (C), Δ cc(d, t), and (D) Δ mf(d, t) for linked disease-tissue pairs (red circles) and 
non-linked disease-tissue pairs (green squares). The insets in panels (B–D) compare the total number of Δ > 0 
cases with the total number of Δ < 0 cases. Listed z-scores are the results of the Mann-Whitney U test applied to 
the comparison of GO similarities of linked disease-tissue pairs and non-linked disease tissue pairs.
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(iii) A large portion of the identified disease-tissue associations are significant even in the case of a more strin-
gent threshold of = .⁎z 2 0E . The bipartite disease-tissue network obtained for = .
⁎z 2 0E  is an almost exact subset of 
the original network obtained for = .⁎z 1 0E  (Supplementary Section V and Fig. S7).
Finally, as we demonstrated in Figs 7 and S8, combining the tissue-specific modules with the interactome 
allowed us to filter out the less relevant disease genes for arthritis and macular degeneration. Consequently, our 
findings could considerably improve the predictive power of the interactome for diseases, allowing the construc-
tion of more accurate disease modules.
Methods
Significance of Gene Expression. We use expression data from 64 non-diseased tissues. We convert probe 
ids to gene ids using the U133 annotation platform. From 13, 460 proteins, only 10, 434 proteins were annotated 
to probe ids, the basis of our subsequent analysis.
To quantify the expression significance of gene i in tissue t, we calculate the average expression 〈 E(i)〉 and the 
standard deviation of a gene’s expression across all considered tissues σE(i). The significance of gene expression 
in tissue t is defined as
σ= − .z i t E i t E i i( , ) ( ( , ) ( ) )/ ( ) (1)E E
Figure 7. Tissue-specific filtering. To demonstrate the filtering effect of tissue-specificity we consider genes 
associated with macular degeneration. Node sizes correspond to gene expression significance in liver tissue. 
Blue nodes correspond to genes in the connected component of the macular degeneration with expression 
significance of zE > 1.0. Green nodes correspond to genes with zE > 1.0 which are not part of the macular 
degeneration connected component. Red nodes correspond to genes with zE < 1.0. (A), The scatter plot of 
GWAS association significance as a function of gene expression significance in liver. (B), Macular degeneration 
genes and links among them. Numeric values correspond to GWAS association significance. The most relevant 
macular degeneration genes form the connected component of the macular degeneration. Note that there 
are two genes with zE < 1.0 that have high GWAS significance scores: HTRA1 with p-value of p = 4 × 10−60 
(− Log(p) = 59) and F13B with p = 1.210−50 (− Log(p) = 50). This observation can be explained as follows. 
The locus of p = 4 × 10−60 is close to two the genes ARMS2 and HTRA1. Genes expressed in the liver are from 
complementary and lipid metabolism pathways. At the same time, the ARMS2 is from inflammatory pathway38. 
HTRA1 is not expressed in the liver as per NCBI UniGene. We also note that the apparent association for 
CFHR2-5 and F13B could be due to their proximity to CFH39. This, again, supports our observation that F13B is 
not expressed in the liver.
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Tissue Specificity of Disease. To test if disease d has a significant connected component in tissue t, we first 
compile the tissue-specific interactome that consists of genes with expression significance zE ≥ 1.0 in tissue t and 
interactions between them. Next, we map genes associated with disease d onto the tissue-specific interactome and 
then measure the size of the largest connected component S and the total number of disease genes Stotal expressed 
in tissue t (Fig. 3A).
To test the significance of the observed disease module we assume that disease genes do not preferentially 
interact in the tissue-specific interactome. With this null hypothesis, we select Stotal genes randomly in the 
tissue-specific interactome and determine the resulting size of the largest connected component Srand. We repeat 
the same procedure 1, 000 times to obtain the distribution Prand(S). Assuming the normality of Prand(S), we use 
the z-score to compute the significance of the real data with the threshold of z ≥ 1.6 for modules to be larger than 
expected by chance.
Gene Ontology Similarity of Disease Modules. The Gene Ontology database36 annotates genes and 
their products with specific molecular functions (mf), biological processes (bf), and cellular components (cc). 
The molecular function similarity of two genes, i and j, is defined as the Simpson similarity of their molecular 
function terms, Smf (i) and Smf (j):
∩
=
| |
| | | |
S i S j
S i S j
mf
( ) ( )
min( ( ) , ( ) ) (2)
ij
mf mf
mf mf
We define the molecular function similarity of a disease d, as the average pairwise molecular function similar-
ity of genes related to this disease:
∑=
− ≠
d
N d N d
mf ( ) 2
( )( ( ) 1)
mf ,
(3)
full
i j
ij
where N(d) is the number of genes associated with diseases d and the summation runs through all pairs of genes 
associated with disease d. Similarly, we define the tissue-specific molecular function similarity of disease d as
∑=
− ≠
d t
N d t N d t
mf( , ) 2
( , )( ( , ) 1)
mf ,
(4)i j
ij
where N(d, t) is the number of genes associated with disease d that are expressed in tissue t, and the summation 
runs through all pairs of disease-related genes expressed in tissue t. Biological process and cellular component 
similarities are defined similarly using, respectively, biological process or cellular component annotation terms.
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